Abbott Laboratories (ABT) Change in Receivables (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Change in Receivables data on file, last reported at $42.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 83.97% year-over-year to $42.0 million; the trailing twelve-month figure through Mar 2026 stood at $432.0 million (down 46.13% YoY), and the FY2025 full-year result was $652.0 million, down 5.64% from the prior year.
• Change in Receivables advanced to $42.0 million in Q1 2026, from -$222.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $751.0 million in Q1 2022 to a low of -$530.0 million in Q3 2022.
• A 5-year average of $106.4 million and a median of $158.0 million in 2024 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 637.14% in 2022, while the deepest fall reached 280.42% in 2022.
• Tracing ABT's Change in Receivables over 5 years: stood at -$341.0 million in 2022, then surged by 80.06% to -$68.0 million in 2023, then jumped by 332.35% to $158.0 million in 2024, then slumped by 240.51% to -$222.0 million in 2025, then soared by 118.92% to $42.0 million in 2026.
• Business Quant data shows ABT's Change in Receivables at $42.0 million in Q1 2026, -$222.0 million in Q4 2025, and $202.0 million in Q3 2025.